A pill that can help stop the development of breast cancer has been made by the pharmaceutical company Pfizer, it has emerged.
The pill, which is now available in Europe, has a range of side effects, including erectile dysfunction and reduced fertility, according to Pfizer.
It is part of a new class of treatments that could be rolled out within the next two years, Pfizer said.
The first drug to be marketed by Pfizer was called a “preliminary report”, or PTR, a report on the efficacy and safety of a drug in patients who have had no treatment.
Pfizer said the preliminary report was only the first step in the development process and that the next step would be to conduct a controlled clinical trial in a large group of people with cancer to confirm the efficacy of the pill.
The new PTR was first developed in the US in the 1990s and has been approved for use by Pfiser and a number of other companies.
It was later used to treat some of the most common forms of the disease, such as breast and ovarian cancers.
It has been marketed to more than 50 countries, including Japan, South Korea and the United Kingdom.
The latest pill is being marketed in Europe for people with breast cancer who are undergoing chemotherapy.
It will be available in three price ranges, from €1,500 ($1,914) for a three-pack to €4,600 ($5,619) for four-packs, the company said.
Pill prices are based on a 10-year average of the average cost of drugs in Europe and the US, according the drugmaker.PPD’s main target is to find the best pill to be available to people who have already had treatment and for whom there is no other option.
The PTR could also be used for people who are waiting for the next dose of treatment to take place, Pfizers chief medical officer Dr Mark Wylie said.
“This pill is the next generation of the PTR.
It’s the first in a new generation of pill that will be in the pipeline for the long term,” he said.
“The next pill will be the best.”
He added that there was a “huge opportunity” to find a pill for people waiting for treatment to come in.
“It is important that we understand the impact of the treatment,” he added.
“We need to understand what the potential is and what the long-term impacts are and we need to find ways to deliver the right pill.”
The US has been working on a new version of the Pill that has a longer half-life than the current PTR drug.
Dr Wyliie said the US had not been able to develop the new pill for breast cancer patients because the US Food and Drug Administration was still reviewing the safety and efficacy of its new drug.
He said Pfizer had developed the drug in the last two years.
“Pfiser is taking the next phase of this project very seriously and we are taking every opportunity to deliver,” he told reporters in a conference call on Thursday.
“If we can develop a pill that is safe, effective and easy to take, we can deliver this pill to a wider population.”
The PPD pill is manufactured in Germany and the company is working with Pfizer’s European manufacturing partner Bayer.
The drugmaker has also developed a pill to treat kidney and bladder cancer and other types of cancers, but the FDA has not approved that treatment.
The US is not the only country working on new PPD pills.
In January, the French government said it was looking at making a new pill that would prevent ovarian cancer from spreading to other parts of the body, but it had not yet decided whether to make the pill available to women.
“The PPR is an important step in our efforts to develop a safer, more effective drug for the treatment of breast, ovarian and other cancers,” Dr Wylien said.